Treatment for Low Risk HIV-1 Infection
common.study.values.description
“Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)”
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of 6 once-monthly doses of oral islatravir (60 mg and 120 mg) compared with placebo in adults at low risk of HIV-1 infection
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - Islatravir
Islatravir administered orally in capsule form once monthly for 24 weeks
Drug - Placebo
Placebo for islatravir administered orally in capsule form once monthly for 24 weeks
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low- Risk for HIV-1 Infection
common.study.values.clinical-trial-id
NCT04003103
participant.views.study.view.id
aOYprd
